CNS Pharmaceuticals, Inc. Common Stock

The glioblastoma multiforme market is expected to grow at a CAGR of 13.2% from 2026-2036, driven by next-generation therapies entering late-stage development. The market was valued at USD 900 million in 2025 across the 7MM, with approximately 38,000 incident cases. Key players including Avita Biomedical, Kazia Therapeutics, Laminar Pharma, and ot...

CNS Pharmaceuticals, a biopharmaceutical company, is developing novel treatments for brain and central nervous system cancers. The company's lead drug candidate, Berubicin, is in a late-stage pivotal trial, and it has recently in-licensed another promising drug, TPI-287, for glioblastoma treatment.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perfo...

Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales guidance below estimates. UPS reported a fourth-quarter fiscal 2023 revenue decline of 7.8% year-over-year to $24.92 billion, missing the consensus of $25.43 bi...

Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) shares rose sharply in today’s pre-market trading as the company posted upbeat results for its second quarter. Super Micro Computer reported quarterly earnings of $5.59 per share, beating the analyst consensus estimate of $4.93. The company reported quarterly sales of $3.67 billion, which to...